CORRECTION

Correction to: Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences

Henrik Svedsater · Helen A. Doll · Jake Macey · Gail Miles ·
Lisa Bradshaw · Magdalena Vanya

Published online: September 3, 2021
© Springer Healthcare Ltd., part of Springer Nature 2021

Correction to: Adv Ther (2018) 35:1378–1399
<https://doi.org/10.1007/s12325-018-0760-7>

There is an error in the DOI link of the original publication. The error has been resolved.

The original article can be found online at <https://doi.org/10.1007/s12325-018-0760-7>.

H. Svedsater (✉)
Value Evidence and Outcomes, GSK, GSK House,
Brentford, Middlesex, UK
e-mail: henrik.x.svedsater@gsk.com

H. A. Doll · J. Macey
ICON, ICON Clinical Outcome Assessments,
Abingdon, UK

G. Miles
BreathingSpace, Rotherham, UK

L. Bradshaw
Centre for Workplace Health, Northern General
Hospital, Sheffield, UK

M. Vanya
ICON Plc, San Francisco, CA, USA